Cushing's syndrome with adrenal suppression and masked hyperandrogenism by high-dose medroxyprogesterone acetate for treatment of endometrial cancer in a young woman with polycystic ovarian syndrome

Endocrine. 2015 Nov;50(2):519-21. doi: 10.1007/s12020-015-0722-7. Epub 2015 Aug 23.
No abstract available

Publication types

  • Case Reports
  • Letter

MeSH terms

  • Adult
  • Antineoplastic Agents, Hormonal / adverse effects*
  • Cushing Syndrome / chemically induced*
  • Endometrial Neoplasms / drug therapy*
  • Female
  • Humans
  • Hyperandrogenism / chemically induced*
  • Medroxyprogesterone Acetate / adverse effects*
  • Polycystic Ovary Syndrome*

Substances

  • Antineoplastic Agents, Hormonal
  • Medroxyprogesterone Acetate